Profiel
Charity D.
Scripture served as the Chief Development Officer at Bellicum Pharmaceuticals, Inc. from 2019 to 2024.
Prior to that, she worked as the Vice President of Business and Development Operations at ACELYRIN, Inc. She completed her undergraduate degree at Hamilton College (New York), her graduate degree at Dartmouth Medical School, and her doctorate at the University of North Carolina at Chapel Hill.
Eerdere bekende functies van Charity Scripture
| Bedrijven | Functie | Einde |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 23-02-2024 |
| ACELYRIN, INC. | Corporate Officer/Principal | - |
Opleiding van Charity Scripture
| Hamilton College (New York) | Undergraduate Degree |
| Dartmouth Medical School | Graduate Degree |
| University of North Carolina at Chapel Hill | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ACELYRIN, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
